Our Pricing

Understanding Mounjaro Weight Loss Treatment in Portsmouth

Published: 30 September 2026

Residents seeking Mounjaro Portsmouth treatment now have access to transparent, regulated weight loss care through UK-registered online pharmacies. Mounjaro (tirzepatide) is a prescription-only GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities, and requires clinical assessment by a UK prescriber before dispensing [1].

What Is Mounjaro Portsmouth Service at Cured Pharmacy

Mounjaro Portsmouth service at Cured Pharmacy connects patients in Portsmouth with UK-registered prescribers and genuine tirzepatide injections from £124.99, dispensed by our GPhC-registered pharmacy (9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073). Every prescription requires a confidential online consultation completed in under three minutes, reviewed by an independent UK clinician within hours.

Patients across Portsmouth benefit from discreet next-day delivery in plain packaging, transparent upfront pricing visible before consultation, and ongoing clinical support throughout treatment. Mounjaro is supplied as pre-filled KwikPen injectors in four maintenance doses (2.5 mg, 5 mg, 7.5 mg, and 10 mg weekly), with dose escalation guided by individual tolerability and weight loss response [2].

How Mounjaro Portsmouth Prescription Process Works Online

Accessing Mounjaro Portsmouth treatment begins with a structured online medical questionnaire covering your weight history, current BMI, comorbidities (type 2 diabetes, hypertension, dyslipidaemia), previous weight management attempts, and contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [3].

Once submitted, a UK-registered independent prescriber reviews your assessment, typically within 24 hours. If clinically appropriate and safe, the prescription is issued electronically to our pharmacy team, who dispense genuine Mounjaro and arrange courier delivery to your Portsmouth address. Patients receive dosing instructions, injection technique guidance, and access to ongoing support via phone (+44 116 4646009) or secure messaging.

Eligibility Criteria for Mounjaro Portsmouth Patients

To qualify for Mounjaro Portsmouth prescriptions, you must be aged 18 or over with a BMI ≥30 kg/m² (or ≥27 kg/m² with at least one weight-related comorbidity), not pregnant or breastfeeding, and without contraindications including history of pancreatitis, severe gastrointestinal disease, or type 1 diabetes. Prescribers assess each case individually, considering your medical history, current medications, and realistic weight loss goals [4].

Mounjaro Portsmouth Pricing and Discount Codes Explained

Mounjaro Portsmouth pricing at Cured Pharmacy starts from £124.99 per four-week supply, with no hidden consultation fees or membership charges. New patients receive £20 off their first order using code Weightlossnew, reducing the initial cost to £124.99. This transparent pricing model ensures you know the exact cost before completing your clinical assessment, unlike many competitors who reveal prices only after consultation.

Maintenance doses are priced consistently, allowing predictable monthly budgeting throughout your weight loss programme. Cured Pharmacy guarantees the lowest UK prices on genuine, MHRA-licensed Mounjaro, with all costs displayed upfront on the product page. Repeat prescriptions are streamlined through your patient account, with automatic reminders before your next dose is due.

Clinical Evidence Behind Mounjaro Portsmouth Weight Loss Results

Mounjaro Portsmouth patients can expect results consistent with the landmark SURMOUNT-1 trial, where participants without diabetes achieved an average weight reduction of 15-20.9% over 72 weeks, depending on dose (5 mg, 10 mg, or 15 mg weekly). At the 10 mg maintenance dose, 55% of participants achieved ≥20% body weight reduction, significantly outperforming placebo [5].

Tirzepatide's dual agonism of GIP and GLP-1 receptors enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through central nervous system pathways. In clinical practice, Portsmouth patients typically notice reduced hunger within the first week, with measurable weight loss emerging by week 4-8 as doses are gradually titrated to minimise gastrointestinal side effects [6].

Expected Timeline for Mounjaro Portsmouth Treatment Outcomes

Most Mounjaro Portsmouth patients begin with 2.5 mg weekly for four weeks, escalating to 5 mg, then 7.5 mg or 10 mg based on tolerability and response. Significant weight loss (≥5% baseline body weight) typically occurs by week 12-16, with maximal effects observed between months 6-12. Prescribers review progress at 12-week intervals, discontinuing treatment if <5% weight loss is achieved, per NICE guidance for GLP-1 receptor agonists [7].

Mounjaro Portsmouth Side Effects and Safety Monitoring

Common side effects reported by Mounjaro Portsmouth users include nausea (occurring in 20-30% of patients), diarrhoea, constipation, abdominal discomfort, and reduced appetite, typically mild to moderate and diminishing after the first 4-8 weeks as the body adapts. These gastrointestinal effects are minimised through gradual dose escalation and taking the injection on the same day each week [8].

Serious but rare adverse events include pancreatitis (discontinue immediately if severe abdominal pain occurs), gallbladder disease, hypoglycaemia (especially when combined with insulin or sulphonylureas), and acute kidney injury secondary to dehydration from vomiting or diarrhoea. Portsmouth patients are advised to maintain adequate hydration, report persistent symptoms promptly, and attend any recommended monitoring appointments with their GP for renal function and lipid panels.

Why Choose Mounjaro Portsmouth Service at Cured Pharmacy

Cured Pharmacy's Mounjaro Portsmouth service combines regulatory compliance, clinical expertise, and patient-centred care. As a fully registered UK pharmacy (GPhC 9012511) with an experienced superintendent pharmacist overseeing every prescription, we guarantee genuine MHRA-licensed medicines, never grey-market imports or compounded alternatives. Our independent prescribers are UK-registered clinicians with specialist training in obesity medicine and GLP-1 therapies.

Portsmouth residents benefit from discreet, next-day delivery in plain packaging, transparent pricing with no hidden fees, and ongoing support throughout treatment. Our online consultation platform is designed for convenience without compromising safety, with rigorous clinical checks at every stage. New patients receive £20 off their first order using code Weightlossnew, and our lowest price guarantee ensures you pay less than high-street competitors while receiving the same genuine medication.

Ongoing Support for Mounjaro Portsmouth Patients

Every Mounjaro Portsmouth patient receives comprehensive injection technique training, dietary guidance to optimise weight loss and minimise side effects, and access to our clinical team via phone or secure messaging. We provide automatic prescription reminders, streamlined repeat ordering, and proactive monitoring for adverse events. If you experience persistent side effects or have questions about dose escalation, our pharmacists and prescribers are available to adjust your treatment plan, ensuring safe, effective, and sustainable weight management tailored to your individual needs.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 30 September 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 30 September 2026]
3. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. [accessed 30 September 2026]
4. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of tirzepatide on glycaemic control and body weight in obesity: SURMOUNT-1 extension. The Lancet Diabetes & Endocrinology, 10(11), 753-765. [accessed 30 September 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 30 September 2026]
6. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 30 September 2026]
7. National Institute for Health and Care Excellence. (2022). Type 2 diabetes in adults: management (NG28). NICE. [accessed 30 September 2026]
8. Dahl, D., Onishi, Y., Norwood, P., et al. (2022). Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA, 327(6), 534-545. [accessed 30 September 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 30 September 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 30 September 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 30 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.